ciclopirox (loprox) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ciclopirox is an antifungal medication indicated for the treatment of seborrheic dermatitis (Loprox trade name) and onychomycosis of fingernails and toenails due to Trichophyton rubrum (Penlac trade name). The drug exerts its action by chelating Fe3+ and Al3+, resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.   NCATS

Chemistry

  • SMILES: Cc1cc(C2CCCCC2)n(O)c(=O)c1
  • InChIKey: SCKYRAXSEDYPSA-UHFFFAOYSA-N
  • Mol. Mass: 207.27
  • ALogP: 2.44
  • ChEMBL Molecules:
    ciclopirox  
    ciclopirox olamine  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.1214 - $85.8300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridinone | 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone ethanolamine salt | batrafen | ciclopirox | ciclopirox ethanolamine | ciclopiroxolamine | ciclopirox olamine | ciclopiroxum | cicloprox | cyclopirox | cyclopyroxolamine | dafnegin-csc | hoe 296 | hoe-296 | hoe-296b | loprox | mycoster | penlac | rv4104a

Organizations (52)

Research & Development (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (33)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (4)


 

Candidiasis

Dermatitis, Seborrheic

Onychomycosis

Tinea Pedis

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Dermatitis, Seborrheic (Phase 4)

Dermatomycoses (Phase 4)

Foot Dermatoses (Phase 4)

Hematologic Neoplasms (Phase 1)

Hodgkin Disease (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Onychomycosis ()

Pharmacokinetics (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Quality of Life (Phase 4)

Tinea Pedis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial Organizations: 20

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue